Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

Technology Transfer: Before the Bayh-Dole Act

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
629 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Mar 30, 2010

Joseph Allen, technology transfer expert and President, Joseph Allen and Associates, speaks at the Fourth Annual Celebration of Technology and Innovation at Emory University. In this segment Allen describes the research-industry relationship prior to passage of the Bayh-Dole act.

About Joseph Allen

Joseph Allen, President, Joseph Allen and Associates: "30 Years of U.S. Technology Policy in 30 Minutes (Along with Thoughts on the Future)"

Joseph Allen is a 30-year veteran of national efforts to foster public/private sector commercialization partnerships. He served as a professional staff member on the U.S. Senate Judiciary Committee with former Senator Birch Bayh (D-In) and was the key staffer securing passage of the Bayh-Dole Act, opening up collaborations between research universities and U.S. industry. In 1999 the Association of University Technology Managers awarded Allen the prestigious Bayh-Dole Award for this achievement. He created the consulting firm Joseph Allen and Associates in 2008, and his clients include the Association of University Technology Managers and the Biotechnology Industry Organization.

About Technology Transfer at Emory University

Emory University's technology transfer program has one of the most robust product pipelines of any university in the country, with one of the nation's leading programs for guiding technology developed in the laboratory through the patenting and licensing process to the marketplace and into the hands of consumers and patients. Since the 1990s, Emory has received more than $775 million in licensing revenues from drugs, diagnostics, devices and consumer products.

The technology transfer program has resulted in 27 licensed therapeutic products, medical devices, and diagnostics already in the marketplace and 12 more in human clinical trials. Emory has launched 47 start-up companies resulting from licensed discoveries. The most widely used drugs for HIV/AIDS, diagnostic tests for genetic disorders, drugs for cancer, a technology to improve angioplasty, and imaging software for diagnosing cardiovascular disease are among the many Emory discoveries now commercially available for patients and physicians.

For more information, see http://www.ott.emory.edu

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more